Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Infliximab and Low Dose Alemtuzumab in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

Daniel Kobrinski, DO, Tulio E. Rodriguez, MD, Scott E. Smith, MD PhD, Stephanie B. Tsai, MD MA, Zeina Al-Mansour, MD, Mala Parthasarathy, MS, Patrick J. Stiff, MD

Blood (2016) 128 (22): 5795.

https://doi.org/10.1182/blood.V128.22.5795.5795

Published: 2016

Journal Articles

Early Post-Transplantation Tacrolimus Levels Correlate with Acute Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation from Related and Unrelated Donors

Patrick A Hagen, MD MPH, Daniel Kobrinski, DO, Zeina Al-Mansour, MD, Stephanie B. Tsai, MD MA, Mala Parthasarathy, MS, Stephanie Kliethermes, PhD, Tulio E. Rodriguez, MD, Scott E. Smith, MD PhD, Patrick J. Stiff, MD

Blood (2016) 128 (22): 3429.

https://doi.org/10.1182/blood.V128.22.3429.3429

Published: 2016

Journal Articles

High Dose Intravenous Busulfan and Melphalan Followed By Bortezomib (BuMelVel) As Conditioning With Autologous Stem Cell Transplantation (ASCT) For Patients With Multiple Myeloma (MM)

Danielle Sterrenberg, MD, Patrick J Stiff, MD, Mala Parthasarathy, MS, Aileen Go, MD, Scott E. Smith, MD, PhD, Tulio E. Rodriguez, MD

Blood (2013) 122 (21): 3376.

https://doi.org/10.1182/blood.V122.21.3376.3376

Published: 2013

Journal Articles

Myeloablative Conditioning With Intravenous Busulfan and Pentostatin (Bu/Pent) Vs. Total Body Irradiation and Cyclophosphamide (TBI/Cy) For Elderly Patients With Acute Myeloid Leukemia Or Myelodysplasia

Shikha Jain, MD, Patrick J Stiff, MD, Scott E. Smith, MD, PhD, Aileen Go, MD, Mala Parthasarathy, MS, Tulio E. Rodriguez, MD

Blood (2013) 122 (21): 5450.

https://doi.org/10.1182/blood.V122.21.5450.5450

Published: 2013

Journal Articles

Transplant Strategies For The Initial Management Of Mantle Cell Lymphoma: A Single Institution Analysis

Camille Adeimy, MD, Daniel Kobrinski, DO, Patrick J Stiff, MD, Tulio E. Rodriguez, MD, Aileen Go, MD, Mala Parthasarathy, MS, Scott E. Smith, MD, PhD

Blood (2013) 122 (21): 5533.

https://doi.org/10.1182/blood.V122.21.5533.5533

Published: 2013

Journal Articles

Prognostic Value Of Disease Status At Time Of Allogeneic Transplant For Relapsed Non-Hodgkin’s Lymphoma

Shams Bakhos, MD, Brubaker L Aleah, PhD, Mala Parthasarathy, MS, Aileen Go, MD, Tulio E. Rodriguez, MD, Patrick J Stiff, MD, Scott E. Smith, MD, PhD

Blood (2013) 122 (21): 3412.

https://doi.org/10.1182/blood.V122.21.3412.3412

Published: 2013

Journal Articles

Cardiac Complications Following Allogeneic Bone Marrow Transplantation: Evaluation of Risk Factors, Outcomes and Enhanced Screening for At Risk Populations.

Michael Henry, BS, Rong Guo, MS, Mala Parthasarathy, MS, John Lopez, MD, Patrick Stiff, MD

Blood (2012) 120 (21): 3070.

https://doi.org/10.1182/blood.V120.21.3070.3070

Published: 2012

Journal Articles

Long Term Follow-up of Allogeneic Transplantation Using BEAM Chemotherapy for Patients with Hodgkin's Lymphoma Who Relapse After Autologous Transplantation: Importance of Minimal Residual Disease At Transplant.

Urszula A Sobol, MD, Tulio E. Rodriguez, MD, Scott E. Smith, MD, PhD, Aileen Go, MD, Ross Vimr, MD, Mala Parthasarathy, MS, Rong Guo, MS, Patrick Stiff, MD

Blood (2012) 120 (21): 3131.

https://doi.org/10.1182/blood.V120.21.3131.3131

Published: 2012

Journal Articles

High Dose Intravenous Busulfan (BU) and Melphalan (MEL) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM)

Tulio E. Rodriguez, M.D., Patrick J. Stiff, MD, Scott E. Smith, MD, PhD, FACP, Jonathan L. Kaufman, MD, Mary Lee, RN, Mala Parthasarathy, MS, Zachary M. Earley, Sagar Lonial, MD, David H. Vesole, MD, PhD

Blood (2010) 116 (21): 1355.

https://doi.org/10.1182/blood.V116.21.1355.1355

Published: 2010

Journal Articles

Phase III Randomized Stem Cell Mobilization Trial Comparing Standard Vs Double-Dose G-CSF Vs Standard Doses of G-CSF Plus GM-CSF in Hard to Mobilize Patients Undergoing An Autologous Hematopoietic Stem Cell Transplant (HSCT).

Elizabeth Berger, BA, Christopher Seet, MBBS, Mala Parthasarathy, MS, Tulio Rodriguez, MD, Scott E. Smith, MD, PhD, Amir Toor, MD, Mary Lee, RN, Cecilia Petrowsky, MSN, Mary Fox-Geiman, PharmD, Patrick Stiff, MD

Blood (2009) 114 (22): 3228.

https://doi.org/10.1182/blood.V114.22.3228.3228

Published: 2009

Journal Articles

Effectiveness of Reduced Toxicity Conditioning Regimen with Intravenous Busulfan Plus Pentostatin (BUPENT) in Patients Older Than 50 Years with Advanced Hematologic Malignancies.

Tulio E. Rodriguez, MD, Mala Parthasarathy, MS, Scott E. Smith, MD, PhD, David H. Vesole, MD, PhD, Zachary M. Earley, Aaron T. Gerds, MD, Amir A. Toor, MD, Patrick J. Stiff, MD

Blood (2009) 114 (22): 3331.

https://doi.org/10.1182/blood.V114.22.3331.3331

Published: 2009

Journal Articles

Autopsies Post Hematopoietic Stem Cell Transplant: A Reassessment of Their Role in Patient Management.

Craig C. Hofmeister, MD, Mala Parthasarathy, MS, M.T., Cheryl Czerlanis, MD, Patrick J. Stiff, MD

Blood (2005) 106 (11): 1332.

https://doi.org/10.1182/blood.V106.11.1332.1332

Published: 2005

Journal Articles

Allogeneic Stem Cell Transplantation (SCT) Using Rabbit-ATG (Thymoglobulin®) and 2-Gy Total Body Irradiation (TBI): Reliable Early Engraftment with Minimal Acute Graft Vs. Host Disease (AGVHD).

Amir A. Toor, MD, Tulio Rodriguez, MD, Najeeb Mohideen, MD, Mala Parthasarathy, MS, Patrick J. Stiff, MD

Blood (2004) 104 (11): 2312.

https://doi.org/10.1182/blood.V104.11.2312.2312

Published: 2004

NARROW

Infliximab and Low Dose Alemtuzumab in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

Early Post-Transplantation Tacrolimus Levels Correlate with Acute Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation from Related and Unrelated Donors

High Dose Intravenous Busulfan and Melphalan Followed By Bortezomib (BuMelVel) As Conditioning With Autologous Stem Cell Transplantation (ASCT) For Patients With Multiple Myeloma (MM)

Myeloablative Conditioning With Intravenous Busulfan and Pentostatin (Bu/Pent) Vs. Total Body Irradiation and Cyclophosphamide (TBI/Cy) For Elderly Patients With Acute Myeloid Leukemia Or Myelodysplasia

Transplant Strategies For The Initial Management Of Mantle Cell Lymphoma: A Single Institution Analysis

Prognostic Value Of Disease Status At Time Of Allogeneic Transplant For Relapsed Non-Hodgkin’s Lymphoma

Cardiac Complications Following Allogeneic Bone Marrow Transplantation: Evaluation of Risk Factors, Outcomes and Enhanced Screening for At Risk Populations.

Long Term Follow-up of Allogeneic Transplantation Using BEAM Chemotherapy for Patients with Hodgkin's Lymphoma Who Relapse After Autologous Transplantation: Importance of Minimal Residual Disease At Transplant.

High Dose Intravenous Busulfan (BU) and Melphalan (MEL) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM)

Phase III Randomized Stem Cell Mobilization Trial Comparing Standard Vs Double-Dose G-CSF Vs Standard Doses of G-CSF Plus GM-CSF in Hard to Mobilize Patients Undergoing An Autologous Hematopoietic Stem Cell Transplant (HSCT).

Effectiveness of Reduced Toxicity Conditioning Regimen with Intravenous Busulfan Plus Pentostatin (BUPENT) in Patients Older Than 50 Years with Advanced Hematologic Malignancies.

Autopsies Post Hematopoietic Stem Cell Transplant: A Reassessment of Their Role in Patient Management.

Allogeneic Stem Cell Transplantation (SCT) Using Rabbit-ATG (Thymoglobulin®) and 2-Gy Total Body Irradiation (TBI): Reliable Early Engraftment with Minimal Acute Graft Vs. Host Disease (AGVHD).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only